EVOK - Evoke Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.7020
-0.0140 (-1.96%)
At close: 4:00PM EDT

0.7100 +0.01 (1.14%)
Pre-Market: 8:22AM EDT

Stock chart is not supported by your current browser
Previous Close0.7160
Open0.7200
Bid0.0000 x 1300
Ask0.0000 x 1200
Day's Range0.7000 - 0.7200
52 Week Range0.7000 - 3.4000
Volume217,216
Avg. Volume896,261
Market Cap12.234M
Beta (3Y Monthly)1.65
PE Ratio (TTM)N/A
EPS (TTM)-0.4600
Earnings DateMar 5, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.00
Trade prices are not sourced from all markets
  • Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs
    Zacks11 days ago

    Dr. Reddy's (RDY) Inks Deal to Acquire Portfolio of 42 ANDAs

    Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.

  • Benzinga23 days ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • GlobeNewswire24 days ago

    Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its 505(b)(2) New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. The CRL, which cites fewer issues than the recent multidisciplinary review letter, states that FDA has determined it cannot approve the NDA in its present form and provides recommendations to address the two remaining approvability issues in an NDA resubmission.

  • Benzinga28 days ago

    Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

    Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally ...

  • GlobeNewswirelast month

    Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S. Food and Drug Administration’s (FDA) multi-disciplinary review (DR) letter that was received on March 1, 2019 in association with the Gimoti 505(b)(2) New Drug Application (NDA). In addition, the Company requested a meeting with the FDA prior to the Prescription Drug User Fee Act (PDUFA) action date of April 1, 2019. The purpose of this meeting is to obtain FDA’s feedback on the Company’s responses.

  • GlobeNewswire2 months ago

    Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

    Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration (FDA) for Gimoti™ 505(b)(2) New Drug Application (NDA)April 1, 2019 Prescription.

  • GlobeNewswire2 months ago

    Evoke Pharma Receives Preliminary FDA Communication on Gimoti™ NDA

    Evoke Pharma, Inc. (EVOK), today announced the receipt of a multi-disciplinary review (DR) letter from the U.S. Food and Drug Administration (FDA) in association with the Gimoti 505(b)(2) New Drug Application (NDA). A DR letter is used by the FDA to convey preliminary thoughts on deficiencies identified during the initial stage of NDA review. Although a DR letter reflects preliminary comments that are subject to change and does not reflect a final FDA decision on the NDA, approval of Gimoti by the PDUFA date of April 1, 2019 is uncertain given the letter.

  • GlobeNewswire2 months ago

    Evoke Pharma Schedules Conference Call and Webcast for Fourth Quarter and Full-Year 2018 Financial Results

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2018 on Wednesday, March 6, 2019, after the market closes. Participants should dial 1-877-407-0789 (United States) or 1-201-689-8562 (International) and mention Evoke Pharma. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.evokepharma.com.

  • GlobeNewswire4 months ago

    Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced a partnership with Novos Growth Partners (NGP) to commercialize Gimoti™, the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. NGP will manage the commercial operations for a dedicated sales team to market Gimoti to gastroenterologists and other targeted health care providers, if approved. NGP will also provide non-dilutive working capital for commercialization costs prior to and following product launch.

  • Loss-Making Evoke Pharma, Inc. (NASDAQ:EVOK) Expected To Breakeven
    Simply Wall St.4 months ago

    Loss-Making Evoke Pharma, Inc. (NASDAQ:EVOK) Expected To Breakeven

    Evoke Pharma, Inc.'s (NASDAQ:EVOK): Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The US$44m market-cap posted Read More...

  • GlobeNewswire5 months ago

    Evoke Pharma Reports Third Quarter 2018 Results

    April 1, 2019 PDUFA date for Gimoti™ NDA Cash runway extended through June 2019 SOLANA BEACH, Calif., Nov. 13, 2018 -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty.

  • Simply Wall St.6 months ago

    Shareholders Should Check The Ownership Structure Of Evoke Pharma Inc (NASDAQ:EVOK)

    If you want to know who really controls Evoke Pharma Inc (NASDAQ:EVOK), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...

  • Generic-Drugs Stock Outlook: No Respite from Pricing Issues
    Zacks7 months ago

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

    Generic-Drugs Stock Outlook: No Respite from Pricing Issues

  • Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
    Zacks7 months ago

    Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead

    Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.

  • Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA
    Zacks8 months ago

    Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

    The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.

  • At $2.8701, Is Evoke Pharma Inc (NASDAQ:EVOK) A Buy?
    Simply Wall St.11 months ago

    At $2.8701, Is Evoke Pharma Inc (NASDAQ:EVOK) A Buy?

    Evoke Pharma Inc (NASDAQ:EVOK), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months. WithRead More...

  • Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven
    Simply Wall St.11 months ago

    Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven

    Evoke Pharma Inc’s (NASDAQ:EVOK): Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. On 31 December 2017,Read More...